Alzheimer disease (AD) is the most common contributor to dementia in the world, but
strategies that slow or prevent its clinical progression have largely remained elusive, until …

Recent Aβ-immunotherapy trials have yielded the first clear evidence that removing
aggregated Aβ from the brains of symptomatic patients can slow the progression of …

Alzheimer's disease (AD) is heterogenous at the molecular level. Understanding this
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …

Psoriasis is a common inflammatory disease of especially high recurrence rate (90%) which
is suffered by approximately 3% of the world population. The overexpression of reactive …

Early Alzheimer's disease (AD) is associated with hippocampal hyperactivity and decreased
sleep quality. Here we show that homeostatic mechanisms transiently counteract the …

Lysosomes are catabolic organelles that contribute to the degradation of intracellular
constituents through autophagy and of extracellular components through endocytosis …

Despite a significant focus on the photochemical and photoelectrical mechanisms
underlying photobiomodulation (PBM), its complex functions are yet to be fully elucidated …

Abstract Background Progression of Alzheimer's disease leads to synapse loss, neural
network dysfunction and cognitive failure. Accumulation of protein aggregates and brain …

Cells keep their proteome functional by the action of the proteostasis network, composed of
the chaperones, the ubiquitin-proteasome system and autophagy. The decline of this …

Alzheimer's disease (AD) is the most common type of neurodegenerative disease and a
health challenge with major social and economic consequences. In this review, we discuss …